Cingulate initiates final study for ADHD asset CTx-1301

Cingulate announced that it has commenced its final FDA-required study, which is a food effect study, for CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder, ADHD. A data readout from the study is expected by the end of 2024. Additionally, Cingulate has raised over $10 million in additional capital since the middle of August 2024, 58% of this amount from its at the market facility, and has received notification from Nasdaq that Cingulate is now in compliance with Nasdaq listing requirements.